{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.43","upperLimit":"12.57","value":"11.43"},{"groupId":"OG001","lowerLimit":"5.57","upperLimit":"16.14","value":"8.43"},{"groupId":"OG002","lowerLimit":"5.43","upperLimit":"8.29","value":"7.86"},{"groupId":"OG003","lowerLimit":"7.29","upperLimit":"18.00","value":"8.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from the date of first dose of pomalidomide until the date progressive disease (PD) was first observed or until the date of death due to any cause, whichever occurred first. Participants who did not have PD or had not died at the time of analysis were censored at the time of their last disease assessment or at the start of new anticancer therapy, whichever occurred first. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar CSF cytology were previously negative and became positive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG000","title":"Diffuse Intrinsic Pontine Glioma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG001","title":"Ependymoma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG002","title":"High-grade Glioma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG003","title":"Medulloblastoma"}],"paramType":"MEDIAN","populationDescription":"The intent-to-treat population includes all enrolled participants, regardless of whether they received any treatment or not","reportingStatus":"POSTED","timeFrame":"From the first dose of pomalidomide to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 71 months)","title":"Kaplan-Meier Estimate of Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"weeks"}